Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals has filed a complaint against Alnylam Pharmaceuticals in the Business Litigation Session (BLS) of the Massachusetts Superior Court for misappropriation and misuse of trade secrets and practices, unjust enrichment, unfair competition and false advertising.
Subscribe to our email newsletter
The suit alleges Alnylam exploited its confidential relationship as a collaborator with Tekmira to engage in inappropriate and harmful conduct concerning Tekmira’s proprietary lipid nanoparticle (LNP) siRNA delivery technology, resulting in damage to Tekmira’s intellectual property and business interests.
Tekmira believes it has rights to Alnylam’s pipeline products.
In addition, Tekmira will also seek the profits that Alnylam has unjustly received from collaborations based on the wrongful use of Tekmira’s technology.
Tekmira president and CEO Mark Murray said they believe this is the right and only course of action to achieve their goal, and they are fully committed and prepared to pursue this lawsuit until they have a fair and satisfactory resolution.